# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Canaccord Genuity analyst Joseph Vafi maintains Open Lending (NASDAQ:LPRO) with a Hold and lowers the price target from $7 t...
Needham analyst Mayank Tandon maintains Open Lending (NASDAQ:LPRO) with a Buy and lowers the price target from $8 to $7.
Open Lending (NASDAQ:LPRO) reported quarterly earnings of $0.04 per share which missed the analyst consensus estimate of $0.05 ...
Raymond James analyst John Davis maintains Open Lending (NASDAQ:LPRO) with a Outperform and maintains $8 price target.
JMP Securities analyst David Scharf reiterates Open Lending (NASDAQ:LPRO) with a Market Outperform and maintains $8 price ta...
Canaccord Genuity analyst Joseph Vafi maintains Open Lending (NASDAQ:LPRO) with a Hold and lowers the price target from $7.5...
Shares of Landos Biopharma, Inc. (NASDAQ: LABP) rose sharply during Monday’s session following acquisition news.